BioCentury | Dec 17, 2012
Emerging Company Profile

Haplogen: Mining for host factors

Haplogen GmbH is screening haploid human cells to identify new host factors required for bacterial or viral infection, which it hopes will lead to the development of anti-infectives with less potential for resistance. Haplogen was...
BioCentury | May 16, 2011
Company News

Scolr Pharma drug delivery news

Scolr announced in its 1Q11 earnings that assuming it does not raise additional funding it will be unable to fund its operations through 2Q11. At March 31, the company had $822,000 in cash. The company...
BioCentury | May 17, 2010
Company News

RedHill, Scolr Pharma deal

SCOLR granted RedHill exclusive, worldwide rights to market ondansetron tablets formulated with SCOLR's CDT extended delivery technology. SCOLR will receive up to $600,000 in upfront and milestone payments, plus up to a total of $30...
BioCentury | Feb 7, 2008
Targets & Mechanisms

PPAR-alpha's in cancer

In a paper published in the Proceedings of the National Academy of Sciences , Harvard University researchers demonstrated an anticancer effect in mice taking oral doses of the generic dyslipidemia drug fenofibrate. 1 The good safety...
BioCentury | Oct 29, 2007
Company News

Scolr Pharma, Dr. Reddy's deal

The companies partnered to develop and commercialize an undisclosed oral compound for cardiopulmonary indications. DDD will use its Controlled Delivery Technology (CDT) to formulate the compound and will also assist in product scale-up activities. RDY...
BioCentury | Apr 16, 2007
Clinical News

CDT-based fenofibrate tablets: Phase I/II started

DDD started an open-label, crossover, Canadian Phase I/II trial in 36 healthy adults. The trial will compare 3 formulations of immediate-release CDT-based fenofibrate tablets to Tricor fenofibrate 48 mg immediate-release tablets from Abbott Laboratories (ABT,...
BioCentury | Mar 19, 2007
Company News

BioCryst, Scolr Pharma deal

DDD will use its Controlled Delivery Technology (CDT) to develop an oral formulation of BCRX's peramivir to treat seasonal and pandemic influenza. BCRX will own rights to the oral formulation of the neuraminidase inhibitor. An...
BioCentury | Feb 12, 2007
Clinical News

CDT-based ondansetron tablets gastrointestinal data

In an open-label, single-blind, bioavailability study in 29 fasting subjects, a single 24 mg tablet of CDT-based ondansetron produced a blood level profile comparable to 3 individual doses of 8 mg Zofran ondansetron immediate-release tablets....
BioCentury | Oct 2, 2006
Company News

Scolr Pharma deal

DDD will use its Controlled Delivery Technology (CDT) drug delivery platform to co-develop an oral formulation of an undisclosed antiviral compound from an undisclosed U.S. biopharmaceutical company. The compound is being developed for influenza. Further...
BioCentury | Apr 19, 2006
Financial News

Scolr raises $11.8 million

Drug delivery company DDD raised $11.8 million in a private placement of about 2.4 million shares at $5, which is an 8% discount to DDD's close of $5.41 on Monday. Taglich Brothers and Roth Capital...
Items per page:
1 - 10 of 31